These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 12854551)
1. Off-label use of tumor necrosis factor inhibitors on ankylosing spondylitis, ulcerative colitis, and psoriasis. TEC Bull (Online); 2003 Jun; 20(2):9-18. PubMed ID: 12854551 [No Abstract] [Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [TBL] [Abstract][Full Text] [Related]
4. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. Famenini S; Wu JJ J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169 [TBL] [Abstract][Full Text] [Related]
5. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers. Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412 [No Abstract] [Full Text] [Related]
6. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court]. Sieper J Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132 [TBL] [Abstract][Full Text] [Related]
7. [Anti-TNF alfa therapy in ankylosing spondylitis]. Cravo AR; Tavares V; Da Silva JC Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716 [TBL] [Abstract][Full Text] [Related]
8. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842 [No Abstract] [Full Text] [Related]
9. Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies. Tecnologica MAP Suppl; 2001 Jul; ():14-7. PubMed ID: 11718149 [No Abstract] [Full Text] [Related]
10. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis]. Berg PA Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503 [No Abstract] [Full Text] [Related]
11. [Adverse events during biological therapy -- focusing on dermatological side-effects]. Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026 [TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based? Smith MD; Ahern MJ Intern Med J; 2006 Feb; 36(2):72-6. PubMed ID: 16472260 [TBL] [Abstract][Full Text] [Related]
19. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P; Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904 [No Abstract] [Full Text] [Related]
20. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. Ko JM; Gottlieb AB; Kerbleski JF J Dermatolog Treat; 2009; 20(2):100-8. PubMed ID: 18923992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]